Gary A Rosenberg1, Jillian Prestopnik2, John C Adair2, Branko N Huisa2, Janice Knoefel3, Arvind Caprihan4, Charles Gasparovic4, Jeffrey Thompson2, Erik B Erhardt5, Ronald Schrader6. 1. Department of Neurology, University of New Mexico, Albuquerque, New Mexico, USA Department of Neurosciences, University of New Mexico, Albuquerque, New Mexico, USA Department of Cell Biology and Physiology, University of New Mexico, Albuquerque, New Mexico, USA. 2. Department of Neurology, University of New Mexico, Albuquerque, New Mexico, USA. 3. Department of Geriatrics, University of New Mexico, Albuquerque, New Mexico, USA. 4. The MIND Research Network, Albuquerque, New Mexico, USA. 5. Department of Mathematics and Statistics, University of New Mexico, Albuquerque, New Mexico, USA. 6. Clinical and Translational Science Center, Albuquerque, New Mexico, USA.
Abstract
OBJECTIVES: Vascular cognitive impairment (VCI) is a heterogeneous group of cerebrovascular diseases secondary to large and small vessel disease. We hypothesised that biomarkers obtained early in the disease could identify a homogeneous subpopulation with small vessel disease. METHODS: We obtained disease markers in 62 patients with VCI that included neurological findings, neuropsychological tests, multimodal MR and cerebrospinal fluid measurements of albumin ratio, matrix metalloproteinases (MMPs), amyloid-β1-42 and phosphorylated-τ181. Proton MR spectroscopic imaging showed ischaemic white matter and permeability of the blood-brain barrier (BBB) was measured with dynamic contrast-enhanced MRI. We constructed a 10-point Binswanger disease score (BDS) with subjective and objective disease markers. In addition, an objective set of biomarkers was used for an exploratory factor analysis (EFA) to select patients with BD. Patients were followed for an average of 2 years to obtain clinical consensus diagnoses. RESULTS: An initial BDS of 6 or greater was significantly correlated with a final diagnosis of BD (p<0.05; area under the curve (AUC)=0.79). EFA reduced nine objective biomarkers to four factors. The most predictive of BD was the factor containing the inflammatory biomarkers of increased BBB permeability, elevated albumin index and reduced MMP-2 index (factor 2; AUC=0.78). Both measures independently predicted a diagnosis of BD, and combining them improved the diagnostic accuracy. CONCLUSIONS: Biomarkers predicted the diagnosis of the BD type of subcortical ischaemic vascular disease. Using pathophysiological biomarkers to select homogeneous groups of patients needs to be tested in targeted treatment trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES:Vascular cognitive impairment (VCI) is a heterogeneous group of cerebrovascular diseases secondary to large and small vessel disease. We hypothesised that biomarkers obtained early in the disease could identify a homogeneous subpopulation with small vessel disease. METHODS: We obtained disease markers in 62 patients with VCI that included neurological findings, neuropsychological tests, multimodal MR and cerebrospinal fluid measurements of albumin ratio, matrix metalloproteinases (MMPs), amyloid-β1-42 and phosphorylated-τ181. Proton MR spectroscopic imaging showed ischaemic white matter and permeability of the blood-brain barrier (BBB) was measured with dynamic contrast-enhanced MRI. We constructed a 10-point Binswanger disease score (BDS) with subjective and objective disease markers. In addition, an objective set of biomarkers was used for an exploratory factor analysis (EFA) to select patients with BD. Patients were followed for an average of 2 years to obtain clinical consensus diagnoses. RESULTS: An initial BDS of 6 or greater was significantly correlated with a final diagnosis of BD (p<0.05; area under the curve (AUC)=0.79). EFA reduced nine objective biomarkers to four factors. The most predictive of BD was the factor containing the inflammatory biomarkers of increased BBB permeability, elevated albumin index and reduced MMP-2 index (factor 2; AUC=0.78). Both measures independently predicted a diagnosis of BD, and combining them improved the diagnostic accuracy. CONCLUSIONS: Biomarkers predicted the diagnosis of the BD type of subcortical ischaemic vascular disease. Using pathophysiological biomarkers to select homogeneous groups of patients needs to be tested in targeted treatment trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: M Ihara; H Tomimoto; M Kinoshita; J Oh; M Noda; H Wakita; I Akiguchi; H Shibasaki Journal: J Cereb Blood Flow Metab Date: 2001-07 Impact factor: 6.200
Authors: T Erkinjuntti; D Inzitari; L Pantoni; A Wallin; P Scheltens; K Rockwood; G C Roman; H Chui; D W Desmond Journal: J Neural Transm Suppl Date: 2000
Authors: John C Adair; Julius Charlie; John E Dencoff; Jeffrey A Kaye; Joseph F Quinn; Richard M Camicioli; William G Stetler-Stevenson; Gary A Rosenberg Journal: Stroke Date: 2004-04-22 Impact factor: 7.914
Authors: John Weaver; Fakhreya Y Jalal; Yi Yang; Jeffrey Thompson; Gary A Rosenberg; Ke J Liu Journal: J Cereb Blood Flow Metab Date: 2014-02-19 Impact factor: 6.200
Authors: Jon B Toledo; Steven E Arnold; Kevin Raible; Johannes Brettschneider; Sharon X Xie; Murray Grossman; Sarah E Monsell; Walter A Kukull; John Q Trojanowski Journal: Brain Date: 2013-07-10 Impact factor: 13.501
Authors: Charles Gasparovic; Jillian Prestopnik; Jeffrey Thompson; Saeid Taheri; Branko Huisa; Ronald Schrader; John C Adair; Gary A Rosenberg Journal: J Neurol Neurosurg Psychiatry Date: 2013-02-16 Impact factor: 10.154
Authors: Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi Journal: Cell Mol Life Sci Date: 2015-09-24 Impact factor: 9.261
Authors: Erik Barry Erhardt; John C Pesko; Jillian Prestopnik; Jeffrey Thompson; Arvind Caprihan; Gary A Rosenberg Journal: J Cereb Blood Flow Metab Date: 2018-03-07 Impact factor: 6.200
Authors: Gary A Rosenberg; Anders Wallin; Joanna M Wardlaw; Hugh S Markus; Joan Montaner; Leslie Wolfson; Costantino Iadecola; Berislav V Zlokovic; Anne Joutel; Martin Dichgans; Marco Duering; Reinhold Schmidt; Amos D Korczyn; Lea T Grinberg; Helena C Chui; Vladimir Hachinski Journal: J Cereb Blood Flow Metab Date: 2016-01 Impact factor: 6.200
Authors: Branko N Huisa; Arvind Caprihan; Jeffrey Thompson; Jillian Prestopnik; Clifford R Qualls; Gary A Rosenberg Journal: Stroke Date: 2015-07-23 Impact factor: 7.914
Authors: Giuseppe Barisano; Axel Montagne; Kassandra Kisler; Julie A Schneider; Joanna M Wardlaw; Berislav V Zlokovic Journal: Nat Cardiovasc Res Date: 2022-02-07